VSD (Ventricular Septal Defect) Closure — Cost, Top Hospitals & Success Rates | MyMedicPlus

A ventricular septal defect (VSD) is an abnormal communication between the left and right ventricles through the interventricular septum, allowing oxygenated blood to flow from the high-pressure left ventricle into the lower-pressure right ventricle — a left-to-right shunt. VSD is the most common congenital cardiac anomaly, accounting for approximately 20% of all congenital heart defects, with an incidence of 2–5 per 1,000 live births.

The haemodynamic consequences depend primarily on the size of the defect and the ratio of pulmonary to systemic blood flow (Qp:Qs ratio). Small, restrictive VSDs with Qp:Qs below 1.5:1 rarely cause symptoms and frequently close spontaneously in childhood. Moderate to large, non-restrictive defects cause volume overloading of the left ventricle and right heart, increased pulmonary blood flow, and — if uncorrected — progressive pulmonary vascular obstructive disease leading to Eisenmenger syndrome, in which pulmonary arterial pressure exceeds systemic pressure, the shunt reverses (right-to-left), and closure becomes contraindicated.

VSDs are classified anatomically into four types:

• Perimembranous (membranous) VSDs: Located adjacent to the aortic valve in the membranous septum; account for approximately 70% of all VSDs. They are in close proximity to the atrioventricular bundle (Bundle of His) and the right bundle branch, creating a risk of heart block with surgical or device closure.
• Muscular VSDs: Located within the trabecular muscular septum; account for approximately 20%. They may be multiple and fenestrated (Swiss cheese pattern). Many close spontaneously.
• Outlet (subarterial or supracristal) VSDs: Located beneath the pulmonary and aortic valves; account for 5–8%, more prevalent in Asian populations. Rarely close spontaneously and frequently lead to aortic cusp prolapse and regurgitation.
• Inlet (AV canal type) VSDs: Located posterior to the septal leaflet of the tricuspid valve; account for approximately 5%, often associated with Down syndrome as part of an atrioventricular septal defect (AVSD).

VSD closure is indicated for ventricular septal defects that produce haemodynamic consequences requiring intervention. The specific clinical presentations that prompt closure include:

• Heart failure in infants: Large VSDs with unrestricted left-to-right shunting cause pulmonary overcirculation, presenting in the first weeks of life with poor feeding, failure to thrive, tachypnoea, diaphoresis during feeding, and recurrent lower respiratory tract infections. Medical management (diuretics, afterload reduction) bridges the patient to elective surgical closure, typically between 3 and 6 months of age.
• Left ventricular (LV) volume overload: Chronic volume overload from a moderate-to-large shunt causes progressive LV dilation and dysfunction. Closure halts and may reverse this remodelling.
• Significant shunt without symptoms: A Qp:Qs ratio of 1.5:1 or greater with echocardiographic evidence of left heart dilation constitutes an indication for closure even in the absence of overt symptoms, to prevent long-term pulmonary vascular disease.
• Aortic valve prolapse and regurgitation: Outlet (subarterial) VSDs cause the right coronary cusp of the aortic valve to prolapse into the defect due to loss of septal support and Venturi effect. Closure prevents progressive aortic regurgitation; coexisting significant aortic regurgitation requires concurrent aortic valve repair.
• Infective endocarditis: A history of endocarditis affecting a VSD is an independent indication for surgical closure and treatment of the infection.
• Paradoxical embolism: Right-to-left shunting through a VSD in the setting of elevated right heart pressures can allow venous thrombus or air to enter the systemic circulation, causing stroke or systemic embolism. Closure eliminates this pathway.

Patient selection for VSD closure requires comprehensive cardiac evaluation to determine the type of defect, haemodynamic significance, and optimal closure strategy:

Indications for Closure

• Qp:Qs ratio of 1.5:1 or greater with symptoms or evidence of left heart dilation on echocardiography.
• Qp:Qs ratio of 2:1 or greater even in asymptomatic patients with a compliant left ventricle.
• Symptomatic heart failure not controlled by optimised medical therapy.
• History of endocarditis on the VSD.
• Outlet VSD with any degree of aortic cusp prolapse regardless of shunt size.

Absolute Contraindication: Eisenmenger Syndrome

Eisenmenger syndrome — irreversible pulmonary arterial hypertension with pulmonary vascular resistance (PVR) exceeding systemic vascular resistance, resulting in net right-to-left shunting and cyanosis — is an absolute contraindication to VSD closure. Closing the defect in this setting removes the only pressure relief valve for the right ventricle, precipitating acute right heart failure and death. Cardiac catheterisation with oxygen challenge is performed to confirm reversibility when PVR elevation is detected.

Catheterisation and PVR Assessment

When echocardiography suggests elevated pulmonary pressures, right heart catheterisation is performed to measure pulmonary arterial pressure directly and calculate pulmonary vascular resistance (PVR) in Wood units. Closure is considered safe when PVR is less than 8 Wood units with a favourable response to vasodilator challenge (oxygen, nitric oxide). PVR greater than 8 Wood units with no vasoreactivity is a relative or absolute contraindication.

Transcatheter vs Surgical Candidacy

• Transcatheter device closure is appropriate for muscular VSDs of suitable size and location with adequate tissue rims on echocardiography, and increasingly for perimembranous VSDs at experienced centres.
• Surgical closure is required for outlet VSDs, inlet VSDs, VSDs associated with other cardiac anomalies, and VSDs not meeting criteria for transcatheter closure due to defect size, location, or anatomy.

Three primary approaches to VSD closure are available, each with specific indications:

Open-Heart Surgery with Cardiopulmonary Bypass

The gold standard for VSD closure. Under general anaesthesia, the chest is opened via median sternotomy (or right mini-thoracotomy for minimally invasive access). The patient is placed on cardiopulmonary bypass (heart-lung machine) and the heart is arrested with cardioplegia solution. The VSD is exposed through the right atrium (via the tricuspid valve) or right ventricle (ventriculotomy) and closed using:

• Dacron patch closure: A patch of woven polyester (Dacron) is sutured circumferentially around the VSD rim, providing a durable, non-absorbable closure. Standard for large or complex VSDs.
• Autologous pericardial patch: Glutaraldehyde-fixed native pericardium provides an excellent biological material with low thrombogenicity, preferred by some centres for perimembranous VSDs near conduction tissue.
• Primary suture closure: Possible for small, favourable-anatomy muscular VSDs with good tissue rims; avoids patch material but rarely applicable to significant haemodynamic defects.

Surgical closure achieves complete or near-complete closure in over 95% of cases. Operative mortality for isolated VSD closure in otherwise healthy patients is less than 1% at high-volume centres.

Transcatheter Device Closure

Under fluoroscopic and transoesophageal or intracardiac echocardiographic guidance, a delivery catheter is advanced from the femoral vein across the VSD into the left ventricle. A self-expanding nitinol mesh device is deployed to straddle the defect:

• Amplatzer Muscular VSD Occluder: FDA-approved for muscular VSDs; double-disc design with a connecting waist sized to the VSD diameter. Highly effective for mid-muscular defects.
• Amplatzel Membranous (Perimembranous) VSD Occluder: For perimembranous VSDs; asymmetric design to avoid the aortic valve. Used widely in Asia; regulatory approval varies by country. Complete or near-complete closure achieved in 95%+ of cases but carries a risk of complete heart block (2–5%) due to proximity of the conduction system.
• Nit-Occlud (pfm medical) and other devices: Various nitinol coil and disc devices are available in different markets for specific VSD morphologies.

Hybrid Perventricular Closure

In high-risk neonates and infants too small for standard catheterisation, a hybrid approach delivers the occluder device directly through a small ventriculotomy under transoesophageal echo guidance without cardiopulmonary bypass. This bridges very small patients to a definitive approach when their size permits.

Successful VSD closure offers profound short- and long-term haemodynamic and clinical benefits:

• Elimination of the left-to-right shunt: Complete closure immediately restores normal right heart and pulmonary vascular flow, removing the volume load that drives pulmonary vascular remodelling.
• Prevention of Eisenmenger syndrome: Timely closure before irreversible pulmonary arterial changes develop prevents what is otherwise a lethal progressive condition. Children closed before age 2 with appropriate indications have pulmonary vascular disease outcomes equivalent to normal peers.
• Reversal of left ventricular dilation: The chronically volume-overloaded left ventricle progressively normalises in size and function after successful closure, reducing long-term arrhythmia and heart failure risk.
• Improved growth and development in infants: Closure of haemodynamically significant VSDs in infancy results in rapid catch-up of weight, height, and developmental milestones that were impaired by chronic heart failure symptoms.
• High surgical success rates: Open-heart repair achieves complete or near-complete closure (residual shunt below haemodynamic significance) in over 95–98% of cases. Operative mortality at high-volume paediatric cardiac centres is below 1% for isolated VSD repair in otherwise healthy children.
• Transcatheter advantage: Device closure of appropriate muscular VSDs avoids sternotomy and cardiopulmonary bypass, with hospital stay of 1–2 days versus 5–7 days for surgery, more rapid recovery, and equivalent haemodynamic outcomes for suitable defects.
• Elimination of endocarditis risk: After complete closure (confirmed by echocardiography at 6 months), the risk of infective endocarditis attributable to the VSD is effectively eliminated.

VSD closure carries procedure-specific risks that differ between surgical and transcatheter approaches:

Risks Common to Both Approaches

• Complete heart block (CHB): The most feared complication of perimembranous VSD closure, occurring in approximately 1–5% of surgical cases and 2–5% of transcatheter device closures. The Bundle of His runs along the postero-inferior rim of perimembranous VSDs; suture or device pressure on this structure disrupts atrioventricular conduction. CHB requiring permanent pacemaker implantation is a serious, lifelong complication. Delayed-onset CHB after transcatheter closure has been reported up to months after implantation.
• Residual shunt: Incomplete closure leaving a residual defect affects approximately 5–10% of cases initially. Small residual shunts often close spontaneously over months; significant residual shunts may require re-intervention.
• Infective endocarditis: Both patch material and implanted devices carry a small risk of infection, particularly in the first 6 months before complete endothelialisation. Endocarditis prophylaxis (antibiotic cover before dental and invasive procedures) is recommended during this period.

Surgical-Specific Risks

• Cardiopulmonary bypass complications: Including systemic inflammatory response, renal dysfunction, neurological injury (stroke, cognitive effects), and coagulopathy. Risk is higher in neonates and small infants.
• Post-operative bleeding and re-exploration: Occurs in approximately 2–5% of cases. Risk is increased in complex repairs and reoperations.
• Aortic regurgitation: Sutures or retraction near the aortic valve during outlet VSD repair may cause aortic valve injury. Risk is minimised by careful intraoperative technique and echo confirmation before bypass separation.

Transcatheter-Specific Risks

• Device embolisation: Rare but requires urgent surgical retrieval. Risk is minimised by correct device sizing and deployment technique under echo guidance.
• Aortic regurgitation (perimembranous device closure): Impingement of the asymmetric device on the aortic valve can cause new or worsened aortic regurgitation; estimated incidence 1–3%.
• Vascular access complications: Femoral arteriovenous fistula, haematoma, or vessel injury at the catheter insertion site.

Post-closure follow-up is structured around confirming complete closure, monitoring for late complications, and managing residual cardiac issues.

Immediate Post-Operative Period

• After surgical VSD repair, patients spend 24–48 hours in the paediatric intensive care unit for haemodynamic monitoring, chest drain management, and ventilator weaning. Oral feeds are reinstated within 24–48 hours and patients are mobilised rapidly.
• After transcatheter closure, patients are monitored overnight for haemodynamic stability, arrhythmia (including heart block), and access site complications. Discharge the following morning is standard for uncomplicated cases.
• A post-procedure ECG is essential before discharge to detect new conduction abnormalities. Baseline ECG is obtained at discharge and at each follow-up visit.

Echocardiographic Follow-Up

• Before discharge: Transthoracic echocardiogram (TTE) confirms device or patch position, absence of significant residual shunt, aortic and tricuspid valve function, and right ventricular pressure.
• 1 month: TTE to assess device endothelialisation (transcatheter cases), residual shunt, and conduction.
• 6 months: TTE to confirm complete closure. If no residual shunt and no device-related complications: endocarditis prophylaxis is discontinued and activity restrictions are lifted.
• 12 months and annually for 5 years: Clinical review with TTE for late arrhythmia, LV size normalisation, pulmonary pressures, and aortic valve function.

Antiplatelet and Anticoagulation Therapy

• After transcatheter device closure, aspirin (3–5 mg/kg/day) is prescribed for 6 months to prevent device thrombus formation during the endothelialisation process. Clopidogrel may be added for the first 1–3 months at some centres.
• Warfarin or low-molecular-weight heparin is reserved for patients with large device sizes, atrial fibrillation, or high thrombotic risk, as determined individually.

The cost of VSD closure varies substantially based on approach, complexity, institution, and country of treatment:

• VSD type and complexity: Isolated muscular VSD in a healthy infant is the least complex and least expensive repair. Outlet or perimembranous VSDs requiring careful suture technique near conduction tissue and valves are more complex. VSDs associated with other congenital heart defects (tetralogy of Fallot, AVSD, coarctation) require combined repair with significantly higher costs.
• Surgical vs transcatheter approach: Open-heart surgery with cardiopulmonary bypass carries higher hospital costs (operating room, perfusionist, ICU stay, nursing staff) than transcatheter closure. However, device costs can partially offset this difference — Amplatzer occluder devices cost approximately USD 3,000–5,000 each, while patch material for surgery is minimal.
• Device type: Different transcatheter occluder systems have different price points. Amplatzer devices (Abbott Medical) are market-leading and widely used internationally. Other devices may be less expensive in certain markets.
• Intraoperative imaging: Transoesophageal or intracardiac echocardiography during transcatheter closure requires additional equipment and an echocardiographer, adding cost. 3D echocardiographic guidance increases precision but adds further cost.
• Hospital stay: Transcatheter closure typically requires 1–2 days of hospitalisation versus 5–7 days for open-heart surgery, with significant savings on nursing, pharmacy, and support services.
• Country and institution: In the United States, isolated VSD repair costs USD 30,000–80,000 including all hospital and professional fees. In India, equivalent open-heart VSD repair at accredited paediatric cardiac centres costs USD 3,000–8,000, and transcatheter closure USD 4,000–7,000 including device and hospital charges. Countries such as Thailand, Turkey, and Malaysia offer comparable quality at similar price points.

Not all VSDs require closure. Alternative management strategies include:

Observation for Small, Restrictive VSDs

Small VSDs with Qp:Qs below 1.5:1, normal left heart dimensions, and no symptoms are observed clinically with annual echocardiographic follow-up. Spontaneous VSD closure is common in childhood: approximately 50–75% of muscular VSDs and 30–40% of small perimembranous VSDs close spontaneously by age 4–6 years as the child grows. Annual echocardiography monitors for progressive shunting, LV dilation, pulmonary hypertension, or aortic cusp prolapse that would prompt closure referral.

Medical Management of Heart Failure

Large VSDs causing heart failure in infancy are initially managed medically to allow growth before elective surgical repair at 3–6 months of age:

• Diuretics (furosemide, spironolactone): Reduce pulmonary congestion and oedema.
• ACE inhibitors or sacubitril-valsartan: Reduce systemic vascular resistance, decrease left-to-right shunt magnitude, and reduce LV afterload.
• Caloric supplementation: High-calorie formula or nasogastric feeding ensures adequate nutrition in infants with heart failure-related feeding difficulties.

Medical management is not curative and does not close the VSD; it is a bridge to definitive surgery in appropriate timing windows.

Pulmonary Artery Banding (PAB)

Historically, pulmonary artery banding — surgically constricting the main pulmonary artery to reduce pulmonary blood flow — was used to palliate large VSDs in very sick small infants before definitive repair. It requires a second surgical procedure for band removal at time of VSD closure. Modern paediatric cardiac surgical outcomes have made primary complete repair before 6 months the preferred strategy at most centres, relegating PAB to selected complex scenarios (multiple VSDs, very premature neonates).

Targeted Pulmonary Vasodilator Therapy for Eisenmenger Syndrome

When VSD closure is no longer possible due to Eisenmenger syndrome, medical management with pulmonary arterial hypertension (PAH)-targeted therapy — phosphodiesterase-5 inhibitors (sildenafil, tadalafil), endothelin receptor antagonists (bosentan, macitentan), and prostacyclin analogues — can improve haemodynamics, exercise capacity, and survival but is not curative. Heart-lung transplantation or lung transplantation with concurrent VSD repair remains the only curative option in Eisenmenger syndrome.